And yet another "autologous" stem cell approval at the FDA, but more pertinently for OCC investors a little insight into a partnership deal:
https://www.investing.com/news/stock-market-news/earnings-call-biolinerx-announces-fda-approval-of-stem-cell-mobilization-drug-motixafortide-93CH-3239578
"Additionally, BioLineRx has closed an exclusive license agreement with Gloria Biosciences for the development and commercialization of Motixafortide in Asia. This agreement includes an upfront payment of $15 million, with potential milestone and royalty payments totaling up to $250 million. This partnership is significant considering Asia reported over 51,000 cases of multiple myeloma in 2022, marking it as a substantial market."
(Motixafortide is an autologous hematopoietic stem cell-based gene therapy for sickle cell disease - autologous hematopoietic based therapies having seen lots of developments as I have posted above over the last couple of years).
I would expect a similar, but larger deal to emerge with OCC and ATI once its finishing shopping it in the US. More likely $25-50 million in upfront payments and $350-500 million in milestone and all up payments. Its too compelling and too big a market for management to accept less on ATI.
(just my personal expectations from years of research and emerging patterns in the autologous stem-cell regulatory and commercial backdrop)
- Forums
- ASX - By Stock
- OCC
- Stem Cell Therapy advancements
Stem Cell Therapy advancements, page-431
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OCC (ASX) to my watchlist
(20min delay)
|
|||||
Last
45.0¢ |
Change
-0.015(3.23%) |
Mkt cap ! $94.30M |
Open | High | Low | Value | Volume |
47.0¢ | 47.0¢ | 44.8¢ | $101.0K | 221.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 6739 | 44.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
45.0¢ | 9799 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4539 | 0.445 |
3 | 82109 | 0.440 |
2 | 19005 | 0.430 |
1 | 40000 | 0.425 |
3 | 18904 | 0.420 |
Price($) | Vol. | No. |
---|---|---|
0.450 | 9799 | 1 |
0.455 | 30999 | 1 |
0.465 | 7230 | 2 |
0.470 | 59673 | 2 |
0.475 | 20000 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online